Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
Ashenafi Tazebew Amare, Director General at Ethiopian Blood and Tissue Bank Service, shared AFRICARhE‘s post on LinkedIn:
“Closing the anti-D immunoglobulin gap in low- and middle-income countries is not simply a matter of increasing medicine procurement; it requires building sustainable systems that connect maternal health services, blood services, reliable supply chains, equitable financing, and timely access to care.
Every RhD–negative mother should have access to appropriate prophylaxis, regardless of where she lives or her ability to pay.
Strengthening regional collaboration, developing sustainable plasma-derived medicinal product supply systems, and investing in national capacity are essential steps towards preventing avoidable maternal sensitization and haemolytic disease of the fetus and newborn.
No mother should lose the opportunity to have a healthy future pregnancy because a life-saving medicine was unavailable.”
AFRICARhE (African Initiative for Rh Disease Eradication) shared a post on LinkedIn:
“Why Does Plasma Matter for Rh disease?
Rh disease can be prevented by anti-D immunoglobulin. In high-income countries, the introduction of anti-D prophylaxis has led to the near-elimination of Rh disease.
However, in low- and middle-income countries (LMICs), the majority of RhD-negative women still do not receive anti-D prophylaxis, and Rh disease continues to cause hundreds of thousands of deaths and lifelong disabilities.
This global anti-D divide can only be addressed if sufficient affordable anti-D immunoglobulin is available.
However, the availability of this essential medicine depends on a specialized supply chain, starting with suitable plasma donors.
Where does plasma fit into the picture?
Plasma is the starting material for manufacturing plasma-derived anti-D immunoglobulin. Unlike most other plasma-derived medicines, anti-D requires plasma from donors with sufficiently high levels of anti-D antibodies.
These donors are either deliberately immunised or have naturally developed anti-D antibodies following pregnancy or an incompatible transfusion.
The latter group is becoming increasingly rare in high-income countries, where anti-D prophylaxis is widely available. However, due to limited coverage of anti-D prophylaxis, many potential donors may still be found in Africa.
Despite the need for plasma-derived medicines, plasma collection remains limited in many African countries, contributing to dependence on international plasma supplies.
What can be done?
Through collaboration with the Ethiopian Blood and Tissue Bank Service, International Society of Blood Transfusion (ISBT), National Bioproducts Institute NPC, WIRhE Foundation (Worldwide Initiative for Rh Disease Eradication) and other partners, AFRICARhE is contributing to the development of an Ethiopian anti-D source-plasma programme.
The initial phase will assess anti-D antibody levels among naturally immunised RhD-negative women, explore their willingness to donate plasma, and evaluate the feasibility of donor recruitment, screening and sample handling.
The longer-term aim is to establish a nationally governed pathway for plasma collection that could support access to anti-D immunoglobulin.
Strengthening plasma collection is not simply about increasing supply. It is also about building the systems, partnerships and local capacity needed to make essential medicines more accessible and sustainable.”
Stay updated with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health
-
Nov 21, 2026, 19:38Toby Richards: Screening Female Students for Heavy Periods and Anaemia Through the SHINE Programme